US-based company HeartWare, a developer of miniaturised implantable cardiovascular devices, has completed the patient enrolment in the HeartWare ventricular assist system (HVAD system) lateral study.

Lateral is a US investigational device exemption (IDE) prospective, multicentre, single-arm clinical trial which will include up to 145 patients at more than 30 hospitals in North America.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial is designed to evaluate the outcome of patients with end-stage heart failure, awaiting a heart transplant, using an implant with the HVAD Pump through a less-invasive thoracotomy procedure.

"This less invasive surgical technique also benefits patients by delaying the need for full sternotomy until cardiac transplantation, enabling an easier surgical procedure at the time of transplant."

University of British Columbia, Department of Surgery, Division of Cardiovascular Surgery Clinical Professor of Surgery and Hvad Lateral study co-principal investigator Anson Cheung said: "Clinical data from the lateral study has the potential to confirm the observations from prior, single-centre studies evaluating the thoracotomy technique and to help facilitate a discussion of innovative surgical implantation techniques to achieve optimal patient outcomes."

Approved by the US Food and Drug Administration (FDA) in 2012, the HVAD System is said to feature the world’s smallest full-support circulatory assist device, the HVAD Pump.

See Also:

It is implanted next to the heart through a small, lateral thoracotomy incision between the patient’s ribs on the left side of the chest, avoiding abdominal surgery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Loyola University Stritch School of Medicine department of thoracic and cardiovascular surgery professor and heart transplant and assist device programme head Ed McGee said: "This less invasive surgical technique also benefits patients by delaying the need for full sternotomy until cardiac transplantation, enabling an easier surgical procedure at the time of transplant.

"We look forward to monitoring patients through the six-month follow-up period and then reviewing the trial results to help inform the medical community about the potential benefits of the thoracotomy implantation technique."

The HVAD System is used by more than 10,000 patients with advanced heart failure across 47 countries.